Peptides
Tesamorelin
Tesamorelin is a GHRH analog studied in visceral fat and growth hormone research. Below, we compare vendors currently stocking research-grade Tesamorelin — not just a single sales page.
Tesamorelin is a GHRH analog studied in visceral fat and growth hormone research. Below, we compare vendors currently stocking research-grade Tesamorelin — not just a single sales page.
Prices and testing claims are pulled from each vendor's product listing. Always confirm current price and COA (Certificate of Analysis) on the vendor's site before buying.
| Vendor | Price | Purity Testing | Code | |
|---|---|---|---|---|
 SwissChemsBest Value |
$27.95 – $279.50 | Third-party COA | Buy Here → | |
 UK Sarms |
£49.99 – £65.00 | Third-party COA | Auto-applied | Buy Here → |
 Purity Peptides |
$79.99 – $139.99 | Third-party COA | Buy Here → | |
 Amino Vault |
$89.25 – $160.65 | Third-party COA | Buy Here → | |
 American Peptides |
From $120.00 | Third-party COA | Buy Here → |
Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH) and is notably the only compound in this category with FDA approval — marketed as Egrifta for the reduction of excess visceral fat in HIV-associated lipodystrophy.
Research-grade Tesamorelin is typically supplied as a lyophilized powder in sealed vials, commonly at 2mg strength, intended for laboratory research use; the FDA-approved pharmaceutical formulation is a separate, prescription-only product.
Tesamorelin binds GHRH receptors in the anterior pituitary, stimulating pulsatile growth hormone release, which in turn raises IGF-1. Its approved clinical effect on visceral adipose tissue is the best-documented outcome among GHRH analogs, supported by Phase 3 clinical trial data.
Tesamorelin's approved indication is grounded in clinical trials demonstrating reduced visceral adipose tissue in HIV-associated lipodystrophy, and it remains a reference compound in GHRH-pathway body-composition research.
Beyond its approved use, Tesamorelin is studied more broadly as a tool for examining GHRH receptor pharmacology and downstream GH/IGF-1 signaling in metabolic research.
In its FDA-approved clinical use, documented side effects include injection-site reactions, joint pain, swelling, and increased blood glucose; the prescribing information for Egrifta details the full clinical safety profile. Research-grade material sourced outside that regulated supply chain has not undergone the same quality controls.
The FDA-approved clinical dose for Egrifta is 2mg administered by subcutaneous injection once daily, per the product's prescribing information — this reflects the approved clinical protocol, not a recommendation for use of unregulated research material.
Compound X does not sell Tesamorelin directly. We provide independent research, comparisons and vendor links — see the vendor comparison table above for current US, UK, Canada and Australia options.
Tesamorelin's clinical trial data and prescribing information are available via the FDA and are also indexed on PubMed under "Tesamorelin GHRH lipodystrophy."
New guides, vendor comparisons and compound breakdowns every week.